AbbVie Inc.

🇺🇸New York Stock Exchange
Back to all articles
AbbVie Inc. stock analysis ABBV overview
Bullish +62

Adams Diversified Equity Fund Inc. Sells 58,300 Shares of AbbVie Inc ...

📉 Adams Diversified Equity Fund Inc. sold 58,300 shares of AbbVie, reducing its position by 31.1% to hold 129,400 shares worth $28.1 million.

📈 Other institutional investors including Imprint Wealth LLC and Westend Capital Management LLC initiated or boosted their stakes in the fourth quarter.

💰 AbbVie reported Q1 revenue of $15 billion, a 12.4% increase year-over-year that exceeded analyst expectations of $14.72 billion.

📊 The company posted earnings per share of $2.65, beating the consensus estimate of $2.59 by $0.06.

💵 AbbVie declared a quarterly dividend of $1.73 with an ex-dividend date of July 15th and an annualized yield of 2.8%.

📈 Piper Sandler reissued an 'overweight' rating with a $298.00 price target on AbbVie shares.

🔼 Canaccord Genuity raised its price target from $265.00 to $273.00 and maintained a 'buy' rating.

📉 The stock carries a high payout ratio of 340.89% based on the declared dividend amount.

🏥 AbbVie's revenue growth was driven by its portfolio in immunology, oncology, neuroscience, virology, and women's health.

📊 MarketBeat data shows a consensus price target of $253.81 with an average rating of 'Moderate Buy'.

Bullish Signals
  • AbbVie reported revenue of $15 billion, representing a 12.4% year-over-year increase that surpassed analyst expectations of $14.72 billion.
  • The company posted earnings per share of $2.65, beating the consensus estimate of $2.59 by $0.06.
  • Piper Sandler reissued an 'overweight' rating and set a price target of $298.00 on AbbVie shares.
  • Canaccord Genuity raised its price target from $265.00 to $273.00 and reaffirmed a 'buy' rating.
  • Guggenheim reaffirmed a 'buy' rating with a price target of $249.00 on AbbVie stock.
  • Cantor Fitzgerald reiterated an 'overweight' rating on AbbVie shares in its latest research report.
  • AbbVie maintains a quarterly dividend of $1.73, providing an annualized yield of 2.8% to investors.
Risk Factors
  • AbbVie has a high payout ratio of 340.89%, indicating that the declared dividend exceeds current earnings per share.
  • The company reported a negative return on equity of -576.45% for the quarter.
  • Adams Diversified Equity Fund Inc., a significant institutional holder, reduced its position by 31.1% in the first quarter.
Full Analysis
Adams Diversified Equity Fund Inc. reduced its position in AbbVie Inc. by 31.1% in the first quarter, selling 58,300 shares to hold a remaining stake of 129,400 shares valued at $28.1 million. While this major fund decreased its exposure, several smaller institutional investors including Chelsea Counsel Co., Litman Gregory Wealth Management LLC, and Imprint Wealth LLC initiated or significantly increased their positions in the fourth quarter. AbbVie reported strong quarterly financial results released on April 29th, with revenue reaching $15 billion, a 12.4% year-over-year increase that beat analyst expectations of $14.72 billion. The company posted earnings per share of $2.65, surpassing the consensus estimate of $2.59, and maintains a quarterly dividend of $1.73 payable on August 14th to shareholders of record by July 15th. Analyst sentiment remains largely positive with recent upgrades from Piper Sandler and Canaccord Genuity, alongside reaffirmations from Guggenheim and Cantor Fitzgerald. The consensus price target stands at $253.81 based on ratings from multiple firms, reflecting confidence in the company's performance despite a high payout ratio of 340.89%.